• Nexstim received an order for an NBS 6 Therapy System from a new customer in the United States.
• System to be used for therapeutic applications, using an FDA-cleared base unit for Major Depressive Disorder and as an adjunct for OCD.
• Delivery includes a non-disposable configuration with reusable head trackers, targeting lower operating costs and improved clinical workflow.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexstim Oyj published the original content used to generate this news brief on July 03, 2026, and is solely responsible for the information contained therein.